REVO looks to expand use of Atryn with preeclampsia PhIII

Framingham, MA-based rEVO Biologics--formerly GTC Biotherapeutics--is planning to put its drug ATryn through a late-stage study for preeclampsia, looking to see if it can help women extend their pregnancy, helping the women as well as their newborns. The drug was initially approved back in 2009 and is made from the milk of genetically engineered goats. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.